Effects of price cap regulation on pharmaceutical supply chain under the zero markup drug policy
Abstract In 2009, China initiated a zero-markup for drugs (ZMD) policy to prevent profit-oriented behaviors among the healthcare providers and alleviate the financial burden on patients. However, overtreatment still prevails because pharmaceutical producers barrage the doctor-patient relationship with promotional activities. This study considered a pharmaceutical supply chain composed of one pharmaceutical producer and one healthcare provider in the context of the ZMD policy, seeking to derive the optimal decisions of the supply chain by considering three scenarios: (1) no promotional activities or price cap regulation; (2) promotional activities but no price cap regulation; and (3) promotional activities and price cap regulation. By comparing the equilibria of these scenarios, we evaluated the impacts of the producers' promotional activities on supply chain members' decisions, profits, and social welfare, as well as the intervention role played by price cap regulation. Our results indicate that the producers' promotional activities contribute to overtreatment, thereby negatively affecting social welfare and patients with low to moderate financial resources. However, the implementation of price cap regulation can effectively reduce the extent of producers' promotional activities, curb overtreatment, and mitigate the associated harm to social welfare..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Operational research - 23(2023), 4 vom: 13. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xia, Yu [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Healthcare supply chain |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s12351-023-00796-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053068424 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053068424 | ||
| 003 | DE-627 | ||
| 005 | 20231213064641.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230914s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12351-023-00796-4 |2 doi | |
| 035 | |a (DE-627)SPR053068424 | ||
| 035 | |a (SPR)s12351-023-00796-4-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xia, Yu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of price cap regulation on pharmaceutical supply chain under the zero markup drug policy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract In 2009, China initiated a zero-markup for drugs (ZMD) policy to prevent profit-oriented behaviors among the healthcare providers and alleviate the financial burden on patients. However, overtreatment still prevails because pharmaceutical producers barrage the doctor-patient relationship with promotional activities. This study considered a pharmaceutical supply chain composed of one pharmaceutical producer and one healthcare provider in the context of the ZMD policy, seeking to derive the optimal decisions of the supply chain by considering three scenarios: (1) no promotional activities or price cap regulation; (2) promotional activities but no price cap regulation; and (3) promotional activities and price cap regulation. By comparing the equilibria of these scenarios, we evaluated the impacts of the producers' promotional activities on supply chain members' decisions, profits, and social welfare, as well as the intervention role played by price cap regulation. Our results indicate that the producers' promotional activities contribute to overtreatment, thereby negatively affecting social welfare and patients with low to moderate financial resources. However, the implementation of price cap regulation can effectively reduce the extent of producers' promotional activities, curb overtreatment, and mitigate the associated harm to social welfare. | ||
| 650 | 4 | |a Overtreatment |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pharmaceutical promotion |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Social welfare |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Healthcare supply chain |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Li, Jing |4 aut | |
| 700 | 1 | |a Zhang, Zhongyang |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Operational research |d Berlin : Springer, 2001 |g 23(2023), 4 vom: 13. Sept. |w (DE-627)SPR024994596 |w (DE-600)2425760-6 |x 1866-1505 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:4 |g day:13 |g month:09 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12351-023-00796-4 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 4 |b 13 |c 09 | ||